Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
Post-grant challenge in Europe
European Patent Office (EPO) opposition represents an important part of the toolbox for dealing with competitors’ patents. An opposition can knock out a competitor’s patent for a relatively low cost and can, in many European countries, even lead to a stay of parallel national infringement proceedings. Figures from the EPO also show that approximately two thirds of oppositions result in revocation or amendment of the opposed patent.
Despite the commercial advantages of filing an opposition, they are underused. Th e proportion of oppositions filed against granted patents in any given year is only around 5 percent (4.74 percent in 2011), with more life sciences patents being opposed than other technology areas such as electronics (7 percent for biotechnology compared to 2 percent in each of telecommunications and computer technology).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Post-grant patents, AIA, inter partes review, patent validity, EPO